{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:33:15Z","timestamp":1757619195440,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>Cancer patients and survivors are at increased risk of developing heart failure (HF) and heart failure hospitalization (HFH). Yet, the utilization of wireless pulmonary artery pressure sensing devices (PAPSD), like CardioMEMS, in this group is limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>We aimed to explore the utilization of CardioMEMS in managing HF among oncology patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a single-center retrospective study reviewing consecutive patients implanted with the CardioMEMS device between November 11, 2015, and February 21, 2023. We analyzed the device's impact on pulmonary artery pressures and HFH using statistical methods including Cox regression models and correlation studies between NT-proBNP levels and hemodynamic parameters.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study included 28 patients, with hypertension (78%) and hyperlipidemia (78%) as prevalent comorbidities. Most patients had heart failure with preserved ejection fraction (64%). Post-implantation, we observed a reduction in HFH and improvements in pulmonary artery pressures. Cox regression identified prior HFH and elevated pulmonary artery systolic (PAS) and diastolic pressures (PAD) as risk factors for repeat HFH (HR: 1.24, 1.04, 1.07, respectively). Biomarker analysis showed a moderate positive correlation between NT-proBNP and PAD, indicating that higher levels are associated with increased hospital admissions. The device was safe with no sensor failures reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>CardioMEMS shows potential in improving HF management in cancer patients, reducing HFH and enhancing pulmonary artery pressure profiles. These preliminary results advocate for further, larger-scale prospective studies to confirm the benefits and integrate CardioMEMS into cardio-oncology care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s40959-025-00355-0","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T08:11:34Z","timestamp":1752826294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience"],"prefix":"10.1186","volume":"11","author":[{"given":"Abdelrahman","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximillian","family":"Bourdillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Ju Ryoo","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Jewani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaden","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihab","family":"Hamzeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Bernard","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"355_CR1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamacardio.2020.7472","volume":"6","author":"MA Agarwal","year":"2021","unstructured":"Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. JAMA Cardiol. 2021;6:952\u20136.","journal-title":"JAMA Cardiol"},{"key":"355_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2021.07.054","volume":"341","author":"A Matetic","year":"2021","unstructured":"Matetic A, Mohamed M, Miller RJH, et al. Impact of cancer diagnosis on causes and outcomes of 5.9 million US patients with cardiovascular admissions. Int J Cardiol. 2021;341:76\u201383.","journal-title":"Int J Cardiol"},{"key":"355_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","volume":"394","author":"H Strongman","year":"2019","unstructured":"Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394:1041\u201354.","journal-title":"Lancet"},{"key":"355_CR4","unstructured":"The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022;400:563\u2013591."},{"key":"355_CR5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"355_CR6","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1093\/cvr\/cvac132","volume":"118","author":"S de Wit","year":"2023","unstructured":"de Wit S, Glen C, de Boer RA, Lang NN. Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovasc Res. 2023;118:3451\u201366.","journal-title":"Cardiovasc Res"},{"key":"355_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/ehjqcco\/qcac045","volume":"8","author":"O Kobo","year":"2022","unstructured":"Kobo O, Raisi-Estabragh Z, Gevaert S, et al. Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 and 2017. Eur Heart J Qual Care Clin Outcomes. 2022;8:787\u201397.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"355_CR8","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"355_CR9","unstructured":"Hospital Readmissions Reduction Program (HRRP). Available from: https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/acuteinpatient-pps\/hospital-readmissions-reduction-program-hrrp"},{"key":"355_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658\u201366.","journal-title":"Lancet"},{"key":"355_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","volume":"398","author":"J Lindenfeld","year":"2021","unstructured":"Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398:991\u20131001.","journal-title":"Lancet"},{"key":"355_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","volume":"7","author":"PB Adamson","year":"2014","unstructured":"Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935\u201344.","journal-title":"Circ Heart Fail"},{"key":"355_CR13","doi-asserted-by":"publisher","unstructured":"Adamson PB, Abraham WT, Stevenson LW, Desai AS, Lindenfeld J, Bourge RC, Bauman J. Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions. Circ Heart Fail. 2016;9(6):e002600. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002600. PMID: 27220593.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002600"},{"key":"355_CR14","doi-asserted-by":"publisher","first-page":"e006863","DOI":"10.1161\/CIRCHEARTFAILURE.119.006863","volume":"13","author":"DM Shavelle","year":"2020","unstructured":"Shavelle DM, Desai AS, Abraham WT, et al. Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study. Circ Heart Fail. 2020;13:e006863.","journal-title":"Circ Heart Fail"},{"key":"355_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(23)00923-6","volume":"401","author":"JJ Brugts","year":"2023","unstructured":"Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023;401:2113\u201323.","journal-title":"Lancet"},{"key":"355_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jacc.2023.11.030","volume":"83","author":"J Lindenfeld","year":"2024","unstructured":"Lindenfeld J, Costanzo MR, Zile MR, et al. Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2024;83:682\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"355_CR17","doi-asserted-by":"publisher","unstructured":"Mokri H, Clephas PRD, de Boer RA, van Baal P, Brugts JJ, Rutten-van M\u00f6lken MPMH. Cost effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands. Eur J Heart Fail. 2024;26(5):1189-1198. https:\/\/doi.org\/10.1002\/ejhf.3213. Epub 2024 Apr 1. PMID: 38560762.","DOI":"10.1002\/ejhf.3213"},{"key":"355_CR18","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/ehf2.14496","volume":"10","author":"MR Cowie","year":"2023","unstructured":"Cowie MR, Thokala P, Ihara Z, Adamson PB, Angermann C. Real-time pulmonary artery pressure monitoring in heart failure patients: an updated cost-effectiveness analysis. ESC Heart Fail. 2023;10:3046\u201354.","journal-title":"ESC Heart Fail"},{"key":"355_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cardfail.2010.08.002","volume":"17","author":"PB Adamson","year":"2011","unstructured":"Adamson PB, Abraham WT, Aaron M, et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail. 2011;17:3\u201310.","journal-title":"J Card Fail"},{"key":"355_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12471-019-01341-9","volume":"28","author":"JJ Brugts","year":"2020","unstructured":"Brugts JJ, Veenis JF, Radhoe SP, et al. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure\u202f: Design and rationale of the MONITOR HF multicentre randomised clinical trial. Neth Heart J. 2020;28:16\u201326.","journal-title":"Neth Heart J"},{"key":"355_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ahj.2019.04.014","volume":"214","author":"J Lindenfeld","year":"2019","unstructured":"Lindenfeld J, Abraham WT, Maisel A, et al. Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). Am Heart J. 2019;214:18\u201327.","journal-title":"Am Heart J"},{"key":"355_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaccao.2020.06.005","volume":"2","author":"AJ Kanelidis","year":"2020","unstructured":"Kanelidis AJ, Raikhelkar J, Kim G, et al. CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy. JACC CardioOncol. 2020;2:515\u20138.","journal-title":"JACC CardioOncol"},{"key":"355_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ehf2.14219","volume":"10","author":"MS Khan","year":"2023","unstructured":"Khan MS, Khouri MG, Gomez L, Fudim M. Pressures do not equal volumes: implications for heart failure management in patients with CardioMEMS. ESC Heart Fail. 2023;10:716\u201320.","journal-title":"ESC Heart Fail"},{"key":"355_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","volume":"68","author":"RL Prentice","year":"1981","unstructured":"Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373\u20139.","journal-title":"Biometrika"},{"key":"355_CR25","doi-asserted-by":"publisher","first-page":"e009427","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","volume":"15","author":"P Welsh","year":"2022","unstructured":"Welsh P, Campbell RT, Mooney L, et al. Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort. Circ Heart Fail. 2022;15:e009427.","journal-title":"Circ Heart Fail"},{"key":"355_CR26","first-page":"315","volume":"12","author":"B Coles","year":"2023","unstructured":"Coles B, Welch CA, Motiwale RS, et al. Acute heart failure presentation, management, and outcomes in cancer patients: a national longitudinal study. Eur Heart J Acute Cardiovasc Care. 2023;12:315\u201327.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"355_CR27","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","volume":"41","author":"A Bharadwaj","year":"2020","unstructured":"Bharadwaj A, Potts J, Mohamed MO, et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J. 2020;41:2183\u201393.","journal-title":"Eur Heart J"},{"key":"355_CR28","doi-asserted-by":"publisher","first-page":"e009772","DOI":"10.1161\/CIRCHEARTFAILURE.122.009772","volume":"16","author":"H Tie","year":"2023","unstructured":"Tie H, Zhu J, Akin S, et al. Characteristics and Outcome of Patients With a History of Cancer Undergoing Durable Left Ventricular Assist Device Implantation. Circ Heart Fail. 2023;16:e009772.","journal-title":"Circ Heart Fail"},{"key":"355_CR29","doi-asserted-by":"publisher","unstructured":"Irizarry-Caro JA, Song J, Miller C, Desai S, Going J, Fossas-Espinosa J, Fatakdawala MM, Ali A, Iliescu C, Palaskas N, Deswal A, Koutroumpakis E. Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure. Cardiovasc Drugs Ther. 2025;39(3):553-562. https:\/\/doi.org\/10.1007\/s10557-024-07546-4. Epub 2024 Jan 15. PMID: 38224416.","DOI":"10.1007\/s10557-024-07546-4"},{"key":"355_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar AD, Fontana M, Quarta CC, Liedtke M. AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4:427\u201341.","journal-title":"JACC CardioOncol"},{"key":"355_CR31","doi-asserted-by":"publisher","first-page":"e009960","DOI":"10.1161\/CIRCHEARTFAILURE.122.009960","volume":"16","author":"V Thohan","year":"2023","unstructured":"Thohan V, Abraham J, Burdorf A, et al. Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices. Circ Heart Fail. 2023;16:e009960.","journal-title":"Circ Heart Fail"},{"key":"355_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1586\/ers.11.16","volume":"5","author":"RP Frantz","year":"2011","unstructured":"Frantz RP. Hemodynamic monitoring in pulmonary arterial hypertension. Expert Rev Respir Med. 2011;5:173\u20138.","journal-title":"Expert Rev Respir Med"},{"key":"355_CR33","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.healun.2008.04.009","volume":"27","author":"RP Frantz","year":"2008","unstructured":"Frantz RP, Benza RL, Kjellstr\u00f6m B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2008;27:780\u20138.","journal-title":"J Heart Lung Transplant"},{"key":"355_CR34","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966\u201383.","journal-title":"Eur J Heart Fail"},{"key":"355_CR35","doi-asserted-by":"publisher","first-page":"e000666","DOI":"10.1136\/openhrt-2017-000666","volume":"5","author":"T Kamai","year":"2018","unstructured":"Kamai T, Tokura Y, Uematsu T, et al. Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer. Open Heart. 2018;5:e000666.","journal-title":"Open Heart"},{"key":"355_CR36","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","volume":"101","author":"N Pavo","year":"2015","unstructured":"Pavo N, Raderer M, H\u00fclsmann M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874\u201380.","journal-title":"Heart"},{"key":"355_CR37","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.cardfail.2005.04.012","volume":"11","author":"F Knebel","year":"2005","unstructured":"Knebel F, Schimke I, Pliet K, et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail. 2005;11:S38-41.","journal-title":"J Card Fail"},{"key":"355_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.rmed.2006.04.014","volume":"101","author":"R Souza","year":"2007","unstructured":"Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M. Ntprobnp as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med. 2007;101:69\u201375.","journal-title":"Respir Med."},{"key":"355_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2023.05.014","volume":"264","author":"B Ozkan","year":"2023","unstructured":"Ozkan B, Grams ME, Coresh J, et al. Associations of N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, and mortality in US adults. Am Heart J. 2023;264:49\u201358.","journal-title":"Am Heart J"},{"key":"355_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/eci.12234","volume":"44","author":"H Takase","year":"2014","unstructured":"Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44:303\u20138.","journal-title":"Eur J Clin Invest"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00355-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:24:46Z","timestamp":1757258686000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00355-0","relation":{},"ISSN":["2057-3804"],"issn-type":[{"type":"electronic","value":"2057-3804"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived given the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}